Related Experiment Video
Updated: May 30, 2026
Metabolic Labeling of Leucine Rich Repeat Kinases 1 and 2 with Radioactive Phosphate
Published on: September 18, 2013
Pathogenic LRRK2 mutations do not alter gene expression in cell model systems or human brain tissue
Michael J Devine1, Alice Kaganovich, Mina Ryten
1Department of Molecular Neuroscience, UCL Institute of Neurology, London, United Kingdom.
Abstract:
Point mutations in LRRK2 cause autosomal dominant Parkinson's disease. Despite extensive efforts to determine the mechanism of cell death in patients with LRRK2 mutations, the aetiology of LRRK2 PD is not well understood. To examine possible alterations in gene expression linked to the presence of LRRK2 mutations, we carried out a case versus control analysis of global gene expression in three systems: fibroblasts isolated from LRRK2 mutation carriers and healthy, non-mutation carrying controls; brain tissue from G2019S mutation carriers and controls; and HEK293 inducible LRRK2 wild type and mutant cell lines. No significant alteration in gene expression was found in these systems following correction for multiple testing. These data suggest that any alterations in basal gene expression in fibroblasts or cell lines containing mutations in LRRK2 are likely to be quantitatively small. This work suggests that LRRK2 is unlikely to play a direct role in modulation of gene expression, although it remains possible that this protein can influence mRNA expression under pathogenic cicumstances.
Insights
Point mutations in Leucine-Rich Repeat Kinase 2 (LRRK2) cause Parkinson's disease. This study found no significant changes in gene expression related to LRRK2 mutations, suggesting LRRK2 may not directly alter gene expression.
Area of Science:
- Neuroscience
- Genetics
- Molecular Biology
Background:
- Point mutations in Leucine-Rich Repeat Kinase 2 (LRRK2) are a known cause of autosomal dominant Parkinson's disease (PD).
- The precise mechanisms underlying neurodegeneration in LRRK2-related PD remain incompletely understood.
- Investigating gene expression alterations is crucial for elucidating the molecular pathology of LRRK2 PD.
Purpose of the Study:
- To investigate global gene expression profiles in individuals and cell models with LRRK2 mutations.
- To determine if LRRK2 mutations are associated with significant alterations in basal gene expression.
- To explore the potential role of LRRK2 in the modulation of gene expression in Parkinson's disease.
Main Methods:
- Global gene expression analysis was performed using a case-control design.
- Three distinct systems were analyzed: fibroblasts from mutation carriers and controls, brain tissue from G2019S mutation carriers and controls, and inducible HEK293 cell lines with wild-type and mutant LRRK2.
- Statistical analysis included correction for multiple testing.
Main Results:
- No statistically significant alterations in global gene expression were detected across all three systems after correction for multiple testing.
- Any potential changes in basal gene expression associated with LRRK2 mutations in fibroblasts or cell lines appear to be quantitatively minor.
- The findings indicate a lack of substantial impact of LRRK2 mutations on overall gene expression levels under basal conditions.
Conclusions:
- LRRK2 mutations do not appear to directly modulate basal gene expression in the studied models.
- While LRRK2 may not play a direct role in regulating gene expression, its influence under specific pathogenic conditions cannot be entirely ruled out.
- Further research is warranted to understand the precise molecular mechanisms linking LRRK2 mutations to Parkinson's disease pathogenesis.
